SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

FUST (Fusion token) is the companion token of FUSD - with tokenomics which mirror those of a typical cryptocurrency. FUST can be placed in the FUST Fusion Miner and used to mine free FUSD. FUST has tokenomics which mirror those of a typical cryptocurrency, and allows those Degens who buy into the FUSD philosophy - but who also enjoy the thrill of chasing fast green candles - to make their play within the structure of the FUSD ecosystem and benefit from the best of both worlds; the possibility of a fast ride upwards whilst earning a passive income paid in our appreciating stable token courtesy of their FUST bag.

FUST Token

The FUST community is rallying around the token's unique ecosystem, which focuses on generating passive income through its appreciating stablecoin, FUSD. Investors are highlighting this yield-focused model as a sustainable alternative to traditional stablecoins, fueling anticipation for future growth and platform developments.

Bitcoin Cash is a hard fork of Bitcoin with a protocol upgrade to fix on-chain capacity. Bitcoin Cash intends to be a Bitcoin without Segregated Witness (SegWit) as soft fork, where upgrades of the protocol are done mainly through hard forks and without changing the original economic rules of the Bitcoin.  Bitcoin Cash (BCH) is released on 1st August 2017 as an upgraded version of the original Bitcoin Core software. The main upgrade is the increase in the block size limit from 1MB to 8MB. This effectively allows miners on the BCH chain to process up to 8 times more payments per second in comparison to Bitcoin. This makes for faster, cheaper transactions and a much smoother user experience.  Why was Bitcoin Cash Created?  The main objective of Bitcoin Cash is to to bring back the essential qualities of money inherent in the original Bitcoin software. Over the years, these qualities were filtered out of Bitcoin Core and progress was stifled by various people, organizations, and companies involved in Bitcoin protocol development. The result is that Bitcoin Core is currently unusable as money due to increasingly high fees per transactions and transfer times taking hours to complete. This is all because of the 1MB limitation of Bitcoin Core’s block size, causing it unable to accommodate to large number of transactions.  Essentially Bitcoin Cash is a community-activated upgrade (otherwise known as a hard fork) of Bitcoin that increased the block size to 8MB, solving the scaling issues that plague Bitcoin Core today.  Nov 16th 2018: A hashwar resulted in a split between Bitcoin SV and Bitcoin ABC

Bitcoin Cash

Bitcoin Cash is capturing investor interest through its notable resilience and YTD outperformance relative to Bitcoin, with community members actively discussing a potential breakout as the asset maintains bullish technical trends. Speculation is high regarding upcoming network upgrades and whale accumulation, leading many to view the coin as a contrarian, undervalued opportunity for long-term growth.

VanEck ETF Trust - VanEck Agribusiness ETF

VanEck Agribusiness ETF

Investors are increasingly rotating into the agribusiness sector, driving fresh inflows into $MOO as the community anticipates potential food supply constraints and favorable shifts in global agricultural demand. Market participants are actively comparing the VanEck Agribusiness ETF to direct commodity futures, highlighting its appeal as an equity-based defensive play for those seeking structural growth outside of the tech sector.

WorldFinancial

World Liberty Financial ($WLFI) is facing intense scrutiny and volatility following reports of a congressional investigation into its foreign capital dealings and a high-value stake acquisition by UAE-linked investors. The community remains sharply divided, with supporters viewing recent price dips as a strategic buying opportunity tied to potential institutional adoption, while critics continue to label the project as a high-risk venture and a vehicle for self-enrichment.

RAWW MILK COIN

Investors are rallying behind RAWW, a memecoin that has sustained its community for over a year by building an ecosystem of webtoons, games, and music rather than relying on short-term hype. The project is trending as supporters contrast its consistent, unconventional content with traditional market volatility, framing their commitment to the token as a lifestyle-driven "milk-pilled" movement.

London-based Quant Network is set to revolutionise blockchain technology with the development of their blockchain operating system Overledger. The experienced team are determined to fulfil the original vision of the internet by creating an open trusted network for people, machines, and data to operate securely and safely.  Overledger -the first interoperable blockchain operating system that facilitates internet-scale development of decentralised, multi-chain applications. Overledger has the ability to unlock and distribute value and applications across current and future blockchains. It is an agnostic platform that connects the world's networks to blockchains and ensures you're not limited to any single a vendor or technology. Overledger is the only platform that facilitates the development of internet-scales development of decentralised, multi-chain applications.

Quant

Quant (QNT) is trending as community members weigh the asset's long-term utility in enterprise banking and interoperability against ongoing frustration regarding its sluggish price action and correlation with broader market volatility. Investors remain divided, with many aggressively accumulating at current levels in anticipation of a supply shock, while others express exhaustion over the extended consolidation phase.

Shiba Inu (SHIB) is a decentralized, community-led cryptocurrency ecosystem built on the Ethereum blockchain. Originally launched as a meme-based project, it has evolved into a comprehensive financial ecosystem designed to offer a decentralized alternative to traditional banking. Its main value proposition lies in its transition from a social phenomenon into a functional utility network, supported by a vast global community known as the ShibArmy and a commitment to 100% community ownership with no central leadership.  The ecosystem features its own decentralized exchange, ShibaSwap, where users can trade, provide liquidity, and earn rewards. To address Ethereum’s high costs and slow speeds, the project utilizes Shibarium, a Layer 2 scaling solution that processes transactions faster and more affordably.  The project employs a unique three-token model to manage its economy and governance. SHIB serves as the primary currency for trading and payments, while LEASH offers scarcity-based incentives for dedicated supporters. BONE acts as the governance token, allowing holders to vote on proposals through the Doggy DAO and serving as the native gas token for the Shibarium network.

Shiba Inu

Shiba Inu is trending as investors debate the impact of the Digital Asset Market Clarity Act, which could permanently codify the token as a digital commodity and potentially unlock long-term institutional interest. While the community remains divided between speculative hopes of burning supply to reach higher price levels and frustration over extended periods of consolidation, many long-term holders continue to view current price action as a strategic accumulation zone.

$4CHAN is a meme token on the Ethereum Network.   4ChanToken represents a global crypto community that pays homage to the memetic powerhouses of the internet as Pepe, Doge, Shib and all major memes inventor combining them all into one super meme token that is $4CHAN. At its core, 4ChanToken embodies the untamed spirit of the notorious 4chan imageboard, where iconic memes are born, nurtured, and unleashed upon the world. With an unyielding spirit of irreverence and a touch of mischief, $4CHAN has emerged as the darling of meme enthusiasts, internet dwellers, and crypto aficionados alike.   The foundation of 4ChanToken lies in its community. We’ve harnessed the chaotic energy of this digital realm to create a currency that celebrates the power of memetic expression, empowering users to engage in a truly unique and decentralized economy. As a passionate supporter, you’ll join a vibrant ecosystem where dank memes and viral sensations are the lifeblood of commerce. 4ChanToken is more than just a digital currency – it’s the place where memes are born.  The ultimate playground for memelords and crypto degens. Based on the simplicity of holdrs/volume operating a store of value.  The identification of this value is best described as 'digital gold'. That $4chan can ultimately represent a superior store of value relative to all other forms of memecoins by embodying all memes in one token as the factual birthplace of all popular memes.

4Chan

4CHAN is trending as the community positions the token as the definitive 'source code' and index for internet meme culture, drawing comparisons to Bitcoin's early days due to its high-supply, nano-cap status. While some vocal bears dismiss the project as a pump-and-dump, supporters are actively accumulating in anticipation of a 'supercycle' and potential institutional rotation back into foundational meme assets.

iShares Trust - iShares Semiconductor ETF

iShares Semiconductor ETF

The iShares Semiconductor ETF (SOXX) is currently experiencing intense debate as investors weigh ongoing AI-driven infrastructure demand against significant volatility and concerns over sector rotation. While some community members remain bullish on a multi-year AI supercycle, others are cautioning against structural risks, focusing on potential overvaluation and the decay inherent in leveraged bearish instruments.

Invesco DB Multi-Sector Commodity Trust - Invesco DB Agriculture Fund

Invesco DB Agriculture Fund

The Invesco DB Agriculture Fund is trending as investors monitor ongoing food security concerns, potential agricultural export disruptions, and the inflationary impact of elevated commodity prices. Community discussions frequently center on hedging strategies, the relationship between rising energy costs and food prices, and geopolitical tensions influencing global supply chains.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

What's Going On With Cingulate Stock Today?

Cingulate slipped in premarket trading as investors weighed its wider quarterly loss against a fresh patent win and new funding to support its ADHD drug launch plans.read more...

Cingulate (NASDAQ:CING) Releases Quarterly Earnings Results, Misses Estimates By $0.28 EPS

Cingulate (NASDAQ:CING - Get Free Report) announced its earnings results on Wednesday. The company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.28...

Cingulate (CING) Expected to Announce Earnings on Thursday

Cingulate (NASDAQ:CING) will be releasing its Q4 2025 earnings before the market opens on Thursday, March 26. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-3-26-cingulate-inc-stock...

<ul class="summary-bullets"><li>The USPTO cleared a patent filed in November 2023, with a status indicating it has been approved and the patent is expected to be issued.</li><li>The filing covers drug-delivery technologies for neurological treatments, including ADHD.</li><li>The technology supports Cingulate’s Precision Timed Release (PTR) platform, used in CTx-1301, an ADHD drug.</li></ul>Shares of Cingulate, Inc. (CING) jumped over 4% in overnight trading on Sunday after the U.S. Patent and Trademark Office (PTO) cleared a key patent application tied to the company’s ADHD drug platform, adding another potential catalyst ahead of a major regulatory decision expected in May.<a href="https://stocktwits.com/symbol/CING">CING stock</a> snapped four straight sessions of gains on Friday to end nearly 5% lower at $8.69.<h2 class="st-heading-2">Patent Office Clears Cingulate ADHD Drug Patent</h2>Patent records show the USPTO has allowed a patent titled “Trimodal, Precision-Timed Pulsatile Release Tablet.” The application, filed in November 2023, is now listed with the status “Allowed - Notice of Allowance Not Yet Mailed” as of Sunday. An allowed status means the patent examiner has approved the claims, and the patent will be issued once final administrative steps are completed.The inventors listed on the filing include Matthew Brams, Cingulate’s chief medical officer, Raul Silva, its chief science officer, and Arthur Straughn, a co-founder of the company. It also names Cingulate as the applicant. The application covers drug-delivery technologies classified for neurological treatments, including attention-deficit/hyperactivity disorder (ADHD).<h2 class="st-heading-2">How Cingulate’s ADHD Drug Technology Works</h2>The patent application centers on a trimodal pulsatile-release tablet that releases medication at multiple timed intervals throughout the day. The tech aligns with Cingulate’s Precision Timed Release (PTR) platform, which the company is using to develop next-generation treatments for ADHD and other neurological conditions.The approach aims to address common challenges with stimulant medications, including midday rebound and the need for multiple doses. CTx-1301 uses dexmethylphenidate, a stimulant already approved to treat ADHD, delivered through Cingulate’s Precision Timed Release platform. It releases dexmethylphenidate in three timed pulses, with the final dose delivered around the time when many extended-release stimulant medications begin to wear off. The company said the design aims to provide rapid symptom relief in the morning and consistent symptom control into the evening.In 2024, the company received a European patent for its CTx-1301, which covers up to 30 European territories, including the UK. The company also holds patents in Australia, Canada, and Israel.<h2 class="st-heading-2">FDA Decision Looms For ADHD Drug</h2>The patent development comes ahead of a key regulatory milestone for Cingulate’s lead program. In October 2025, the U.S. Food and Drug Administration (FDA) accepted the company’s New Drug Application for CTx-1301 for the treatment of ADHD in children and adults. The agency set a Prescription Drug User Fee Act (PDUFA) target action date of May 31.The application is being reviewed under a regulatory pathway that allows companies to reference existing data for approved ingredients while showing new clinical benefits through different delivery technologies. Cingulate completed Phase 3 trials in adult and pediatric patients before submitting the application. The studies showed improvements in ADHD symptoms and demonstrated sustained efficacy across the day.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for CING shifted to ‘extremely bullish’ from the ‘bullish’ zone over the past month amid a 675% surge in 24-hour message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/cing_ss_png_1c541a03cd.webp" alt="cing ss.png" width="968" height="141"><figcaption>CING sentiment and message volume as of March 15 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/stockchacing/message/647581086">said</a>, “Can’t wait for Monday, interesting week ahead of us.”<stembedurl>https://stocktwits.com/stockchacing/message/647581086</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/fullobullz/message/647578844">said</a>, “Fuel up the rockets, time to ride to moon.”<stembedurl>https://stocktwits.com/fullobullz/message/647578844</stembedurl>CING stock has doubled so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

CING stock has doubled so far this year. (Photo credit: Getty Images)

Cingulate Stock Jumps Overnight: US Patent Office Clears ADHD Drug Filing Ahead Of May FDA Catalyst

The FDA has set May 31 as the PDUFA target date to decide on Cingulate’s ADHD drug CTx-1301.

Why Is CING Stock Jumping Over 4% In Overnight Trading?

Equity

Cingulate (NASDAQ:CING) Trading Up 6.5% - Here's What Happened

Cingulate (NASDAQ:CING) Shares Up 6.5% - Here's Why...

Cingulate (NASDAQ:CING) CEO Shane Schaffer Purchases 6,809 Shares

Cingulate Inc. (NASDAQ:CING - Get Free Report) CEO Shane Schaffer acquired 6,809 shares of the company's stock in a transaction dated Friday, February 6th. The stock was acquired at an average cost...

Cingulate (NASDAQ:CING) CFO Jennifer Callahan Purchases 4,864 Shares

Cingulate Inc. (NASDAQ:CING - Get Free Report) CFO Jennifer Callahan purchased 4,864 shares of the firm's stock in a transaction dated Friday, February 6th. The shares were purchased at an average...

Shane Schaffer Buys 6,809 Shares of Cingulate (NASDAQ:CING) Stock

Cingulate Inc. (NASDAQ:CING - Get Free Report) CEO Shane Schaffer purchased 6,809 shares of Cingulate stock in a transaction that occurred on Friday, February 6th. The stock was bought at an average...

Peter Werth Purchases 19,455 Shares of Cingulate (NASDAQ:CING) Stock

Cingulate Inc. (NASDAQ:CING - Get Free Report) Director Peter Werth acquired 19,455 shares of the company's stock in a transaction dated Friday, February 6th. The shares were purchased at an average...

Retail chatter around Cingulate picked up on Tuesday after Roth Capital Partners raised its price target to $17 from $10 and reaffirmed a ‘Buy’ rating.&nbsp;<a href="https://stocktwits.com/symbol/CING">Cingulate Inc.’s stock</a> snapped a two-day losing streak, rising 2.5% to $4.15 on Tuesday, and added another 1.6% in after-hours trading.The firm said the FDA’s acceptance of Cingulate’s application for its ADHD drug CTx-1301 signals confidence in the treatment’s safety and effectiveness for both children and adults.Roth analysts said the absence of an Advisory Committee review, an earlier-than-expected PDUFA date of May 31, 2026, and a potentially broad label across ADHD patients all strengthen the investment case for Cingulate. They also highlighted the strong approval track record of ADHD stimulants as supportive of the drug’s prospects.The FDA’s acceptance marks a major step forward for CTx-1301, which uses Cingulate’s proprietary Precision Timed Release technology to deliver once-daily, all-day symptom control. The company said Phase 3 data showed rapid onset and sustained efficacy with no serious safety issues reported.The company called the FDA acceptance a “defining milestone”, positioning Cingulate to transition from a development-stage to a commercial-stage company in 2026, pending approval. The firm said commercial preparations are already underway through partnerships with Bend Bio Sciences and Indegene to ensure manufacturing scale-up and market readiness.On Stocktwits, retail sentiment for Cingulate was ‘bullish’ amid an 820% surge in 24-hour message volume.One bullish user highlighted the advantages of Cingulate’s regulatory route, noting it follows a faster and less expensive path typically used for drugs that build on existing approvals with new delivery methods. They noted the company’s silence on social media could hint at buyout interest and said they would only part with their shares for $27.<stembedurl>https://stocktwits.com/StockGuru320/message/632269303</stembedurl>Another bullish user noted that, with the NDA now accepted, the real question for investors was the risk they were taking by not owning the stock at this stage. They added that long-term holders were feeling more confident than ever about the company’s direction.<stembedurl>https://stocktwits.com/Duke1979/message/632260917</stembedurl>Cingulate’s stock has declined 16% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Cingulate’s stock (CING) has declined 16% so far in 2025. (Photo credit: Getty Images)

Cingulate Stock Snaps 2-Day Losing Streak As Roth Hikes Target On ADHD Drug Review; Retail Bets On Buyout Potential

Roth Capital said the FDA’s acceptance shows strong confidence in Cingulate’s ADHD drug, adding that its early PDUFA date and clean regulatory path make it a good investment.

Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using a Precision Timed Release drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The firm initially focused on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). It identifies and evaluates additional therapeutic areas, PTR technology employed to develop future product candidates. Cingulate was founded by Shane J. Schaffer, Craig Steven Gilgallon, Raul R. Silva, Matthew N. Brams in May 2012 and is headquartered in Kansas City, KS.

CING
Cingulate Inc

Feed

News

Sentiment

Fundamentals

Info

Latest CING News

CINGCingulate Inc